Skip to main content
Article thumbnail
Location of Repository

In Vitro Manipulation of Urotensin-II Receptor Expression: Implications of Receptor Density on Ligand Efficacy

By Benjamin Dean Hunt


Many urotensin-II (UT) receptor ligands characterised to date exhibit assay-dependent paradoxical agonist / antagonist properties. This activity is likely to be due to differences in UT receptor density between assays, especially between in vivo and in vitro systems. The present study characterised the effect of UT receptor density on the absolute and relative efficacies of experimental UT ligands (urantide and UFP-803). Two in vitro models were produced allowing the density of UT to be controlled in the presence of a fixed cellular background. \ud 1. Ecdysone-inducible Chinese hamster ovary (CHO) cell-line, allowing UT transcription to be induced by a nuclear steroid hormone, (pon-A). \ud 2. UT-targeting siRNAs, allowing UT translation to be inhibited in CHO cells expressing the human recombinant UT receptor (CHOhUT). \ud The production and characterisation of the first of these models was problematic due to significant expression of UT in the absence of pon-A, therefore affording no advantage over classical in vitro systems. \ud Two UT-targeting siRNAs were transfected into CHOhUT and were shown to knockdown UT expression by 94 & 73% at the mRNA level and 64 & 40% at the functional level. \ud This model has allowed us to control UT receptor density in the presence of a fixed cellular background. We have shown that decreasing the density of UT in CHOhUT reduces the absolute efficacies of experimental UT ligands (urantide and UFP-803). We attribute this effect to reduced mass of ligand-receptor complexes. Reducing the density of UT in CHOhUT does not affect the relative efficacies of the same ligands. We attribute this effect to the absence of a UT receptor reserve over the range of UT densities used. \ud A better understanding of system-dependent efficacy is crucial for effective use of UT ligands in the clinical setting. The technologies employed in this thesis represent an important avenue for future work

Publisher: University of Leicester
Year: 2011
OAI identifier:

Suggested articles


  1. (2008). 100: 574-590). Page 178 Presented as a poster presentation at the joint meeting of the
  2. 6.1 CHOhUT growth medium D-MEM/F-12 (1X) liquid 1:1 (Invitrogen). supplemented with 10% foetal calf serum, penicillin (100 IU/ml) streptomycin (100 μg/ml) and fungizone (2.5 μg/ml). Stock cultures were further supplemented with geneticin (G418; 800 μg/ml).
  3. (2003). A comparison of cerebrospinal fluid and plasma urotensin II concentrations in normotensive and hypertensive patients undergoing urological surgery during spinal anesthesia: a pilot study. Anesth Analg,
  4. (1998). A molecular timescale for vertebrate evolution. Nature,
  5. A new ligand for the urotensin II receptor.
  6. (1995). A novel putative neuropeptide receptor expressed in neural tissue, including sensory epithelia. Biochem Biophys Res Commun,
  7. A Pharmacology Primer.
  8. (1969). A reference preparation for the study of active substances in the caudal neurosecretory system of teleosts.
  9. (2006). Agonists of an ecdysone-inducible mammalian expression system inhibit Fas Ligand- and TRAIL-induced apoptosis in the human colon carcinoma cell line RKO. Cell Death Differ,
  10. (2005). Approaches for chemically synthesized siRNA and vector-mediated RNAi. FEBS Lett,
  11. (2000). Assignment of the GPR14 gene coding for the G-proteincoupled receptor 14 to human chromosome 17q25.3 by fluorescent in situ hybridization. Cytogenet Cell Genet,
  12. (2006). Association of ACE, ACE2 and UTS2 polymorphisms with essential hypertension in Han and Dongxiang populations from north-western China. J Int Med Res,
  13. (2005). Behavioral effects of urotensin-II centrally administered in mice. Psychopharmacology (Berl),
  14. (2000). Ca2+ signalling and muscle disease.
  15. Cardiac actions of central but not peripheral urotensin II are prevented by beta-adrenoceptor blockade.
  16. (2001). Cardiostimulant effects of urotensin-II
  17. (2006). Cell and tissue responses of a range of Urotensin II analogs at cloned and native urotensin II receptors. Evidence for coupling promiscuity. Naunyn Schmiedebergs Arch Pharmacol,
  18. (2006). Cell signalling diversity of the Gqalpha family of heterotrimeric G proteins. Cell Signal,
  19. (2004). Cellular distribution of immunoreactive urotensin-II in human tissues with evidence of increased expression in atherosclerosis and a greater constrictor response of small compared to large coronary arteries. Peptides,
  20. (2001). Central effects of urotensin-II following ICV administration in rats. Psychopharmacology (Berl),
  21. (1995). Cloning and chromosomal mapping of three novel genes, GPR9, GPR10, and GPR14, encoding receptors related to interleukin 8, neuropeptide Y, and somatostatin receptors. Genomics,
  22. (1986). Cloning and sequence analysis of cDNAs encoding precursors of urotensin II-alpha
  23. (1998). Cloning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin II gene in motoneurons of the spinal cord.
  24. (1999). Cloning, sequence analysis and tissue distribution of the mouse and rat urotensin II precursors. FEBS Lett,
  25. (2001). Co-expression of urotensin II and its receptor (GPR14) in human cardiovascular and renal tissues. J Hypertens,
  26. (2007). Comparison of multiple DNA dyes for real-time PCR: effects of dye concentration and sequence composition on DNA amplification and melting temperature. Nucleic Acids Res,
  27. (2001). Comparison of the contractile responses of human coronary bypass grafts and monkey arteries to human urotensin-II. Fundam Clin Pharmacol,
  28. (2001). Conditional transgenic technologies.
  29. (2002). Congestive heart failure and expression of myocardial urotensin II. Lancet,
  30. (1997). Constitutive activity of native thyrotropin-releasing hormone receptors revealed using a protein kinase Cresponsive reporter gene. Endocrinology,
  31. (1997). Continuous fluorescence monitoring of rapid cycle DNA amplification. Biotechniques,
  32. (2000). Contractile responses to human urotensin-II in rat and human pulmonary arteries: effect of endothelial factors and chronic hypoxia in the rat.
  33. (1987). Contraction of major artery segments of rat by fish neuropeptide urotensin II.
  34. Culture of animal cells: a manual of basic technique. fifth ed. 2005:
  35. (2003). Deletion of the UT receptor gene results in the selective loss of urotensin-II contractile activity in aortae isolated from UT receptor knockout mice.
  36. (2006). Delivery Systems for the Direct Application of siRNAs to Induce RNA Interference (RNAi) In Vivo.
  37. (2000). Deltorphin II-induced rapid desensitization of delta-opioid receptor requires both phosphorylation and internalization of the receptor.
  38. (2001). Depressor and regionally-selective vasodilator effects of human and rat urotensin II in conscious rats.
  39. (2009). Desensitisation of native and recombinant human urotensin-II receptors. Naunyn Schmiedebergs Arch Pharmacol,
  40. (2004). Differential effect of urotensin II on vascular tone in normal subjects and patients with chronic heart failure. Circulation,
  41. (2004). Differential levels of "urotensin-II-like" activity determined by radio-receptor and radioimmuno-assays. Peptides,
  42. (2000). Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey.
  43. (1974). DNA ligase: structure, mechanism, and function. Science,
  44. (1992). Drosophila ultraspiracle modulates ecdysone receptor function via heterodimer formation. Cell,
  45. (2001). Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature,
  46. (1996). Ecdysone-inducible gene expression in mammalian cells and transgenic mice.
  47. (2005). Effect of exogenous urotensin-II on vascular tone in skin microcirculation of patients with essential hypertension.
  48. (2002). Effects of human urotensin II in isolated vessels of various species; comparison with other vasoactive agents. Naunyn Schmiedebergs Arch Pharmacol,
  49. (2001). Effects of urotensin II in human arteries and veins of varying caliber. Circulation,
  50. Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure.
  51. (2004). Elevated plasma levels of immunoreactive urotensin II and its increased urinary excretion in patients with Type 2 diabetes mellitus: association with progress of diabetic nephropathy. Peptides,
  52. (2004). Emerging roles of urotensin-II in cardiovascular disease. Pharmacol Ther,
  53. (2001). Evaluation of the tetracycline- and ecdysoneinducible systems for expression of neurotransmitter receptors in mammalian cells.
  54. (1985). Excitation-contraction coupling and the ultrastructure of smooth muscle. Circ Res,
  55. (2001). Expression of urotensin II and urotensin II receptor mRNAs in various human tumor cell lines and secretion of urotensin II-like immunoreactivity by SW-13 adrenocortical carcinoma cells. Peptides,
  56. (1996). Fluid shear stress induction of the transcriptional activator cfos in human and bovine endothelial cells, HeLa, and Chinese hamster ovary cells. Biotechnol Bioeng,
  57. (2005). From heart to mind. The urotensin II system and its evolving neurophysiological role. Febs J,
  58. (1993). Functional ecdysone receptor is the product of EcR and Ultraspiracle genes. Nature,
  59. (1988). Functional receptors for fish neuropeptide urotensin II in major rat arteries.
  60. (1997). Furin: a mammalian subtilisin/Kex2p-like endoprotease involved in processing of a wide variety of precursor proteins.
  61. (2006). G-protein-coupled receptors: past, present and future.
  62. (2004). Genetic variations at urotensin II and urotensin II receptor genes and risk of type 2 diabetes mellitus in Japanese. Peptides,
  63. (1958). Genetics of somatic mammalian cells. III. Long-term cultivation of euploid cells from human and animal subjects. J Exp Med,
  64. (2006). Haplotypes in the urotensin II gene and urotensin II receptor gene are associated with insulin resistance and impaired glucose tolerance. Peptides,
  65. (2006). Heterotrimeric G-proteins: a short history.
  66. (2002). High plasma concentrations of human urotensin II do not alter local or systemic hemodynamics in man. Cardiovasc Res,
  67. (2005). Human urotensin II accelerates foam cell formation in human monocyte-derived macrophages. Hypertension,
  68. (2006). Human Urotensin II in the plasma of anephric subjects. Nephrol Dial Transplant,
  69. (2000). Human urotensin II mediates vasoconstriction via an increase in inositol phosphates.
  70. (2002). Human urotensin II-induced aorta ring contractions are mediated by protein kinase C, tyrosine kinases and Rho-kinase: inhibition by somatostatin receptor antagonists.
  71. (2001). Human urotensin II-induced contraction and arterial smooth muscle cell proliferation are mediated by RhoA and Rho-kinase. Circ Res,
  72. (2003). Human urotensin-II as a novel cardiovascular target: 'heart' of the matter or simply a fishy 'tail'? Curr Opin Pharmacol,
  73. (1999). Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature,
  74. (2000). Human urotensin-II is an endothelium-dependent vasodilator in rat small arteries.
  75. (2000). Human urotensin-II, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular disease. Trends Cardiovasc Med,
  76. (2000). Identification of ligands and coligands for the ecdysoneregulated gene switch.
  77. (2002). Identification of nonpeptidic urotensin II receptor antagonists by virtual screening based on a pharmacophore model derived from structureactivity relationships and nuclear magnetic resonance studies on urotensin II. J Med Chem,
  78. (1999). Identification of the natural ligand of an orphan Gprotein-coupled receptor involved in the regulation of vasoconstriction. Nat Cell Biol,
  79. (2008). Identification of the orphan GPCR, P2Y(10) receptor as the sphingosine-1-phosphate and lysophosphatidic acid receptor. Biochem Biophys Res Commun,
  80. Identification of urotensin II as the endogenous ligand for the orphan G-protein-coupled receptor GPR14.
  81. Identification of urotensin II-related peptide as the urotensin IIimmunoreactive molecule in the rat brain.
  82. Immunolocalization of urotensin II and its receptor in human adrenal tumors and attached non-neoplastic adrenal tissues.
  83. (2006). In vitro and in vivo pharmacological characterization of the novel UT receptor ligand
  84. (2004). Increased expression of urotensin II and its cognate receptor GPR14 in atherosclerotic lesions of the human aorta. Atherosclerosis,
  85. (2008). Increased gene expression of urotensin II-related peptide in the hearts of rats with congestive heart failure. Peptides,
  86. (2003). Increased plasma urotensin II levels in patients with diabetes mellitus. Clin Sci (Lond),
  87. (2002). Increased urotensin II plasma levels in patients with cirrhosis and portal hypertension.
  88. (2007). Influence of hydrodynamic conditions on quantitative cellular assays in microfluidic systems. Anal Chem,
  89. (2004). Ins(1,4,5)P3 metabolism and the family of IP3-3Kinases. Cell Signal,
  90. (1982). Lithium amplifies agonistdependent phosphatidylinositol responses in brain and salivary glands.
  91. (2003). Mathematics of quantitative kinetic PCR and the application of standard curves. Nucleic Acids Res,
  92. (2006). Measurement of [Ca 2+ ]i in whole cell suspensions using fura-2, in Methods in molecular biology: calcium signalling protocols,
  93. (2006). Measurement of phospholipase C by monitoring inositol phosphates using [ H]inositol-labelling protocols in permeabilized cells, in Methods in molecular biology: calcium signalling protocols,
  94. (2002). Molecular and pharmacological characterization of genes encoding urotensin-II peptides and their cognate G-protein-coupled receptors from the mouse and monkey.
  95. (1998). Molecular basis of receptor/G-protein-coupling selectivity. Pharmacol Ther,
  96. (1991). Molecular diversity and function of G proteins and calcium channels. Biol Reprod,
  97. (2002). mRNA-specific reverse transcriptionpolymerase chain reaction from human tissue extracts. Anal Biochem,
  98. (1984). Neuropeptide-induced contraction and relaxation of the mouse anococcygeus muscle.
  99. (1978). Neurosecretion and Neuroendocrine Activity: Evolution, Structure
  100. (2002). No effect on central or peripheral blood pressure of systemic urotensin II infusion in humans.
  101. (2007). Nonclassic endogenous novel [corrected] regulators of angiogenesis. Pharmacol Rev,
  102. (2005). Nonpeptidic urotensin-II receptor antagonists I: in vitro pharmacological characterization of SB-706375. Br
  103. (2000). Orphan-receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1. Br
  104. (2008). Palosuran inhibits binding to primate UT receptors in cell membranes but demonstrates differential activity in intact cells and vascular tissues.
  105. Partial agonist behaviour depends upon the level of nociceptin/orphanin FQ receptor expression: studies using the ecdysoneinducible mammalian expression system.
  106. (2006). Performing quantitative reverse-transcribed polymerase chain reaction experiments. Methods Enzymol,
  107. (2006). Pharmacodynamics and pharmacokinetics of the urotensin II receptor antagonist palosuran in macroalbuminuric, diabetic patients. Clin Pharmacol Ther,
  108. (2004). Plasma concentration of urotensin II is raised in hypertension.
  109. (2002). Plasma levels and cardiovascular gene expression of urotensin-II in human heart failure. Regul Pept,
  110. Plasma urotensin in human systolic heart failure.
  111. (2009). Plasmid uptake by bacteria: a comparison of methods and efficiencies. Appl Microbiol Biotechnol,
  112. (1990). Post-translational processing of prepro-urotensin II. FEBS Lett,
  113. (1998). Potent and specific genetic interference by double-stranded RNA
  114. (2006). Progress towards in vivo use of siRNAs. Mol Ther,
  115. Quantitative detection of reverse transcriptase-PCR products by means of a novel and sensitive DNA stain.
  116. (2004). Ratiometric and nonratiometric Ca2+ indicators for the assessment of intracellular free Ca2+ in a breast cancer cell line using a fluorescence microplate reader. J Biochem Biophys Methods,
  117. (1996). Real time quantitative PCR. Genome Res,
  118. (2003). RNA interference: biology, mechanism, and applications. Microbiol Mol Biol Rev,
  119. (2003). Role of urotensin II gene in genetic susceptibility to Type 2 diabetes mellitus in Japanese subjects.
  120. (2001). Role of urotensin II in patients on dialysis. Lancet,
  121. (2002). Seven-transmembrane receptors. Nat Rev Mol Cell Biol,
  122. (1994). Signal transduction in vascular smooth muscle: diacylglycerol second messengers and PKC action.
  123. (1990). Signal transduction mechanisms involved in hormonal Ca2+ fluxes. Environ Health Perspect,
  124. (1987). Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem,
  125. (1996). SMRT isoforms mediate repression and anti-repression of nuclear receptor heterodimers.
  126. (1995). Structural and functional relationships of heterotrimeric G-proteins. Faseb J,
  127. (2009). Structural determinants involved in the formation and activation of G protein betagamma dimers. Neurosignals,
  128. (2005). Structure-activity relationship study on human urotensin II. J Pept Sci,
  129. (2003). Textbook of Receptor Pharmacology.
  130. (2001). The ecdysone inducible gene expression system: unexpected effects of muristerone A and ponasterone A on cytokine signaling in mammalian cells. Eur Cytokine Netw,
  131. (2003). The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Mol Pharmacol,
  132. (2002). The genetics of RNA silencing. Annu Rev Genet,
  133. (2006). The in vivo effects of human urotensin II in the rabbit and rat pulmonary circulation: effects of experimental pulmonary hypertension.
  134. (1963). The inositol lipids of ox brain.
  135. (2009). The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem,
  136. The neuromedin B receptor antagonist, BIM-23127, is a potent antagonist at human and rat urotensin-II receptors.
  137. (2006). The peptidic urotensin-II receptor ligand GSK248451 possesses less intrinsic activity than the low-efficacy partial agonists SB-710411 and urantide in native mammalian tissues and recombinant cell systems.
  138. (2005). The repertoire of G-protein-coupled receptors in fully sequenced genomes. Mol Pharmacol,
  139. (2007). The response of mammalian cells to doublestranded RNA. Cytokine Growth Factor Rev,
  140. (1998). The role of calcium in activity-dependent neuronal gene regulation. Cell Calcium,
  141. (2007). The role of urotensin II in the metabolic syndrome. Peptides,
  142. (2004). The upregulation of endothelial nitric oxide synthase and urotensinII is associated with pulmonary hypertension and vascular diseases in rats produced by aortocaval shunting. Heart Vessels,
  143. (2001). The urotensin II receptor is expressed in the cholinergic mesopontine tegmentum of the rat. Brain Res,
  144. (2002). Three vasoactive peptides, endothelin-1, adrenomedullin and urotensin-II, in human tumour cell lines of different origin: expression and effects on proliferation. Clin Sci (Lond),
  145. (2008). Three-dimensional model of the human urotensin-II receptor: Docking of human urotensin-II and nonpeptide antagonists in the binding site and comparison with an antagonist pharmacophore model. Proteins,
  146. (2001). Titrating the expression of a Gi protein-coupled receptor using an ecdysone-inducible system in CHO-K1 cells. Receptors Channels,
  147. (2005). Unlocking the secrets of cell signaling. Annu Rev Physiol,
  148. (2004). Urantide mimics urotensin-II induced calcium release in cells expressing recombinant UT receptors.
  149. (2003). Urantide: an ultrapotent urotensin II antagonist peptide in the rat aorta.
  150. (2007). Urotensin II accelerates cardiac fibrosis and hypertrophy of rats induced by isoproterenol. Acta Pharmacol Sin,
  151. (2003). Urotensin II acts centrally to increase epinephrine and ACTH release and cause potent inotropic and chronotropic actions. Hypertension,
  152. (2008). Urotensin II and urotensin II-related peptide activate somatostatin receptor subtypes 2 and 5. Peptides,
  153. (2004). Urotensin II causes fatal circulatory collapse in anesthesized monkeys in vivo: a "vasoconstrictor" with a unique hemodynamic profile. Am J Physiol Heart Circ Physiol,
  154. (2002). Urotensin II evokes potent vasoconstriction in humans in vivo.
  155. (2007). Urotensin II in chronic liver disease: In vivo effect on vascular tone.
  156. (1998). Urotensin II in the central nervous system of the frog Rana ridibunda. Biochemical characterization and immunohistochemical localization.
  157. (2001). Urotensin II induces hypertrophic responses in cultured cardiomyocytes from neonatal rats. FEBS Lett,
  158. (1999). Urotensin II is the endogenous ligand of a G-protein-coupled orphan receptor,
  159. Urotensin II mediates ERK1/2 phosphorylation and proliferation in GPR14-transfected cell lines.
  160. (2004). Urotensin II promotes hypertrophy of cardiac myocytes via mitogen-activated protein kinases. Mol Endocrinol,
  161. (2001). Urotensin II-immunoreactivity in the brainstem and spinal cord of the rat. Neurosci Lett,
  162. (2003). Urotensin II-induced activation of extracellular signalregulated kinase in cultured vascular smooth muscle cells: involvement of cell adhesion-mediated integrin signaling. Life Sci,
  163. (2005). Urotensin II: evidence for cardiac, hepatic and renal production. Peptides,
  164. (2006). Urotensin-II and its receptor (UT-R) are expressed in rat brain endothelial cells, and urotensin-II via UT-R stimulates angiogenesis in vivo and in vitro.
  165. (2004). Urotensin-II-converting enzyme activity of furin and trypsin in human cells in vitro. J Pharmacol Exp Ther,
  166. (2004). Urotensin-II-mediated cardiomyocyte hypertrophy: effect of receptor antagonism and role of inflammatory mediators. Naunyn Schmiedebergs Arch Pharmacol,

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.